---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-007471"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T12:05:08.028700+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology stockholders re-elect directors, ratify auditor, approve equity plan amendment

## Summary
- Re-elected Class I directors Louie Ngar Yee and Steven Chaouki with >6M votes each; 352k broker non-votes.
- Ratified Grant Thornton as independent auditor for FY2023: 6,502,742 for, 3,091 against, 63 abstain.
- Approved amendment to 2021 Equity Incentive Plan allowing annual share increase of 10% of fully diluted outstanding through 2032.

## SEC filing metadata
- accession: 0001564590-23-007471
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000156459023007471/0001564590-23-007471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000156459023007471/maia-8k_20230525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-007471
- JSON: https://secwatch.observer/filing/0001564590-23-007471.json
- Plain text: https://secwatch.observer/filing/0001564590-23-007471.txt

## Key facts
- Shareholder Votes
  MAIA Biotechnology, Inc. shareholders approved Election of Class I directors for three-year terms expiring in 2026 at the 2023-05-25 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: Stockholders re-elected both of the Company’s Class I nominees for director for three-year terms expiring on the annual meeting of stockholders to be held in 2026 or until their successors are duly elected and qualified
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459023007471/0001564590-23-007471-index.htm
- Shareholder Votes
  MAIA Biotechnology, Inc. shareholders approved Ratification of appointment of Grant Thornton LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-25 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: Stockholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459023007471/0001564590-23-007471-index.htm
- Shareholder Votes
  MAIA Biotechnology, Inc. shareholders approved Amendment to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan to include automatic annual increase in shares reserved at the 2023-05-25 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: Stockholders approved an amendment to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the “2021 Plan” ) to include an automatic increase in the aggregate number of shares reserved for awards under the 2021 Plan
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459023007471/0001564590-23-007471-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.